EUCTR2009-014854-14-GB进行中（未招募）1 期
A phase II, open-label, multicentre, 12 month study to evaluate the efficacy and safety of ranibizumab (0.5 mg) in patients with choroidal neovascularization secondary to pathological myopia (PM) - REPAIR
ovartis Pharmaceuticals UK Ltd0 个研究点目标入组 0 人开始时间: 2009年10月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Written informed consent must be obtained before any assessment is performed
- •Male or female outpatients of any race, aged 18 years or older
- •Diagnosis of active primary or recurrent subfoveal or juxtafoveal CNV secondary to PM
- •Diagnosis of high myopia of at least -6 dioptres in the study eye spherical equivalent. For subjects who have undergone prior refractive or cataract surgery in the study eye, the preoperative refractive error in the study eye must have been at least -6 dioptres
- •Patients who have a BCVA score between 78 and 24 letters in the study eye using Early Treatment Diabetic Retinopathy Study (ETDRS)-like grading charts (approximately 6/9 – 6/96 Snellen equivalent)
- •Patients willing and able to comply with all study procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •History of any surgical intervention in the study eye within two months preceding Visit 1 (screening)
- •Previous macular laser photocoagulation, treatment with intravitreal steroids, verteporfin with photodynamic therapy (Visudyne®) or anti-VEGF agents ranibizumab, bevacizumab or pegaptanib sodium (Macugen®) in the study eye
- •Previous treatment with intravenously administered bevacizumab (Avastin®)
- •Prior treatment in the study eye with external-beam radiation therapy, vitrectomy, or transpupillary thermotherapy
- •Previous participation in any studies of investigational drugs within one month preceding Visit 1 (excluding vitamins and minerals)
- •History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
- •History of allergic reaction to fluorescein
- •Concurrent use of systemic anti-VEGF agents
- •Current use of or likely need for systemic medications known to be toxic to the lens, retina or optic nerve, including deferoxamine, chloroquine/ hydroxychloroquine (Plaquenil), tamoxifen, phenothiazines and ethambutol
- •Concomitant use of chronic NSAIDs for more than seven consecutive days or systemic or topical ocular corticosteroids for three or more consecutive days within six months prior to Visit 1. Note that ASA (aspirin) taken as ‘low dose’ up to 100 mg qd for prophylaxis of myocardial infarction and/or stroke is permitted during study
- •Previous treatment with or participation in a clinical trial (for either eye) involving anti angiogenic drugs (pegaptanib, ranibizumab, anecortave acetate or corticosteroids, etc.)
- •Patients who present with CNV of causes other than PM e.g. age-related macular degeneration (AMD), presumed ocular histoplasmosis, angioid streaks, multifocal choroiditis or choroidal rupture
- •Ocular disorders in the study eye that may confound interpretation of study results, including retinal detachment or macular hole (Stage 3 or 4), active intraocular inflammation (grade trace or above) or persistent macular edema due to uveitis or other inflammatory diseases
- •Concurrent disease in the study eye that could compromise visual acuity or require medical or surgical intervention during the 12-month study period
- •Planned or anticipated need for cataract surgery during the 12-month study period
- •Sub or juxtafoveal laser scar in the study eye
- •Vitreous haemorrhage or history of rhegmatogenous retinal detachment or macular hole in the study eye
- •Presence of retinal pigment epithelial tear involving the macula in the study eye
- •History of idiopathic or autoimmune-associated uveitis in either eye
- •Active or suspected ocular, periocular or intraocular infections e.g. conjunctivitis, keratitis, scleritis or endophthalmitis in either eye.
- •History of glaucoma filtration surgery or corneal surgery
- •Extracapsular extraction of cataract with phacoemulsification within 2 months preceding Visit 1, or a history of post-operative complications within the last 12 months preceding Visit 1 in the study eye (uveitis, cyclitis etc.)
- •Uncontrolled glaucoma in the study eye (defined as intraocular pressure = 25 mmHg despite treatment w
研究者
相似试验
已完成
2 期
An open-label, Phase IIa, multi-center, 12-week prospective study to evaluate the safety and efficacy of NOE-105 at a daily dose range of 2.5mg to 15mg in adult and adolescent male patients with Tourette Syndrome (TS).Neurological - Other neurological disordersTourette syndromeACTRN12621000319875oema Pharma Australia Pty Ltd15
进行中（未招募）
1 期
A study to evaluate different doses of a medicine called NOE-105 for the treatment of patients with Tourette Syndrome.Tourette SyndromeMedDRA version: 20.0Level: LLTClassification code 10044127Term: Tourette's syndromeSystem Organ Class: 100000004850EUCTR2021-004424-15-DEoema Pharma Australia Pty Ltd18
进行中（未招募）
不适用
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - SUSTAIMale and female patients =50 years of age with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)EUCTR2005-005921-73-HUovartis Pharma Service AG500
进行中（未招募）
不适用
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab (0.3 and/or 0.5 mg) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - SUSTAIMale and female patients =50 years of age with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)EUCTR2005-005921-73-DEovartis Pharma Service AG500
进行中（未招募）
不适用
A phase IIIb, open-label, multi-center 12 month study to evaluate the safety, tolerability and efficacy of ranibizumab 0.3 mg in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration - NDEUCTR2005-005921-73-ITOVARTIS FARMA600